Showing: 1 - 3 of 46 RESULTS
Banner News Niemann-Pick Type C News Research News

Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million related to NPC drug approval

February 27, 2025 at 7:31 AM EST CELEBRATION, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease …

Announcements DART News DART Walk/Run Niemann-Pick Type C News Past DART Events

7th Annual DART to the Finish Charity Walk Raises Over $160,000

GREENWICH, Conn., September 30, 2024 – Dana’s Angels Research Trust (DART), the nonprofit organization dedicated to funding medical research, education and treatment of the rare childhood disease Niemann-Pick Type C (NPC), often referred to as “childhood Alzheimer’s,” is proud to announce that its 7th annual DART to the Finish Charity Walk, held on September 28, …

Announcements Banner News Niemann-Pick Type C News Research News

FDA Approves 2nd New Drug to Treat NPC

FDA Approves New Drug to Treat Niemann-Pick Disease, Type C | FDA For Immediate Release:September 24, 2024 Today, the U.S. Food and Drug Administration approved Aqneursa (levacetylleucine) for the treatment of neurological symptoms associated with Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing at least 15 kilograms.  “This is the second treatment …